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Section A 
Extended-Answer Questions 
Answer AT LEAST TWO (2) questions. Total Number of Marks:  40 or 60 marks 
This section must be answered in the Answer Booklet provided.  
Each question is worth 20 marks.  Suggested Time allocation for Section A: 90 minutes 
 
Question 1 (Drug development process) 
(a) Draw a thoroughly labelled schematic diagram of the drug development pipeline 
explaining the phases of drug development, potential loops, entry points and 
potential areas of failure. 
[15 marks] 
(b) As chief scientific officer for a major bio-pharma company you are approached 
by a start-up with a proposal for you to partner with them in developing a new 
compound. The compound targets a therapeutic area you are familiar with, but 
the mechanism is novel. The start-up’s compound has reached pre-clinical animal 
studies. What due diligence should you perform on their proposal and what are 
the potential benefits and pitfalls that your company will face in taking the 
compound to market? 
 [5 marks] 
[Total: 20 marks]  
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Question 2 (Development of receptor targeted drugs) 
(a) Describe the chemical bonds involved in drug-receptor interaction. Include some 
relevant examples 
 [5 marks] 
(b)  “Stereochemistry of drug molecules plays an important role in the affinity of 
drugs”.  
Explain this statement with suitable examples 
 [2 marks] 
(c) Indicate what drug-receptor interactions are involved at every arrow shown in the 
structure below. More than one kind of interaction is possible for each letter A, B, 
C, D and E arrows. 
              
[3 marks] 
(d)   Define and provide examples for the following: 
i. Quantitative structure-activity relationship 
ii. Structure-toxicology relationship 
iii. Pharmacophore  
iv. IC-50 
[7 marks] 
(e) Compare and contrast the lock and key theory of receptor-ligand interactions with 
the flexible domain theory? 
[3 marks] 
 [Total: 20 marks] 
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Question 3 (Separation sciences) 
(a) The zombie apocalypse has broken out! Your small band of human survivors has lots 
of chainsaws, but doesn’t have access to any pain relief. In your group’s hiding place 
you find some “anti-animal pest” tablets. You realise that these will contain aspirin 
and paracetemol to poison the pests, but they are also effective analgesics in humans. 
However they will also contain napthelene, which is an irritant.  
You have access to a small chemistry laboratory containing glassware, filters, organic 
solvents, acids and bases.  Describe how you would separate the components of the 
tablets to provide a range of pain medications for your group 
Your supply of tablets contain: 
Silica based binding agent (excipient) – this is solid, non-reactive and insoluble along 
with the following active ingredients: 
 
                          
       Naphthelene   Aspirin   Paracetamol  
[12 marks] 
(b) If you were faced with the problem above, but the tablets contained only aspirin and 
ibuprofen (structure below) (assume the binding agent has been removed and you 
have a solid mixture of the two compounds). What separation technique would you 




[Total: 20 marks]  
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Question 4 (Structural drug development) 
A patient was admitted to hospital for a knee reconstruction surgery a few months ago.  
While they were recovering in the hospital, morphine (a μ-opioid receptor agonist) was 
administered to manage their pain.  After discharge, the patient was prescribed codeine. 
Currently the patient finds that they are relying heavily on their daily dose of codeine to 
function properly.  They believe that they have developed addiction to this pain reliever. 
  
(a) With reference to the structures shown above, describe the pharmacophore and 
structure-activity relationship of μ-opioid receptor agonists  
[7 marks] 
(b) Evaluate the following structures and apply your chemical understanding gained 
from the analysis to recommend appropriate agent(s) for the patient to be weaned off 
their addiction.  Justify your recommendations  
 
[8 marks] 
(c) As a medicinal chemist you are asked to study the interaction of these agents with 
opioid receptors. What instrumental techniques and experimental methods would you 
use for such a study?  
[5 marks] 
 [Total: 20 marks]   
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Question 5 (Drug design process) 
Describe and discuss the roles, advantages and disadvantages of each of the 
following, drawing on examples from the literature as needed: 
i. Rules of 3 and 5 
ii. ClogP vs logP 
iii. logP vs logD 
iv. Pro-drug strategy 
v. Phenotypic screening 
vi. Pre-emptive toxicology  
vii. Expedited regulatory approval 
[20 marks] 
[Total: 20 marks]  
 
 
End of Section A 
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Section B 
Extended-Answer Questions 
Answer AT LEAST TWO (2) questions. Total Number of Marks:  40 or 60 marks 
This section must be answered in the Answer Booklet provided.  
Each question is worth 20 marks.  Suggested Time allocation for Section B: 90 minutes 
_____________________________________________________________________________ 
Question 6 (Instrumental analysis) 
(a) In one sentence, define the following terms: 
i. Metabolomics 
ii. Lipidomics 
iii. Metabolic footprinting 
 [3 marks] 
(b) Using a flowchart, outline the key steps in the metabolomic analysis (profiling) of 
tissue extracts taken from a study of 50 individuals. Include details on sample 
preparation and the suggested analytical platform to be used (note: separation and 
detection method) 
[7 marks] 
(c) Compare and contrast the usefulness of following instrumental techniques in 
relation to metabolomics; and to drug discovery (screening): 
i. Nuclear magnetic resonance 
ii. Gas chromatography – mass spectrometry 
iii. Liquid chromatography – mass spectrometry 
[10 marks] 
 
[Total: 20 marks] 
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Question 7 (Anti-cancer chemotherapy) 
(a) Why are chemotherapy agents not usually subject to Phase I clinical trials? 
[1 mark] 
(b) Side effects of anti-cancer agents are often due to “on pathway” effects. Explain 
the term “on pathway” and discuss the difference between on and off pathway 
effects.  
[2 marks] 
(c) Identify and explain the mechanisms of action for the following anti-cancer 
compounds. In the case of covalent binders, show the full chemical reaction 
mechanism: 
     
             
[17 marks] 
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Question 8 (β-lactam anti-bacterials) 
(a) What is bio-prospecting and how did it influence the “antibiotic revolution”? 
[1 marks] 
(b)   The following compounds are all β-lactam antibiotics. Using these examples, 
explain their mechanism of action; the medicinal chemistry of oral 
bioavailability; and their relative usefulness treating bacteria expressing β-
lactamase. 
           
  Penicillin G   Amoxycillin   Methicillin 
[12 marks] 
(c)   β-lactamase expressing bacterial infections are a major target area for drug 
development. Below are two compounds used in the treatment of these infections. 
Explain the advantages and disadvantages of these two mechanisms for dealing 
with β-lactamase producing bacteria (include structural detail) 
  
Vancomycin           Clavulanic acid 
[6 marks] 
(d)   Why is vancomycin not orally bioavailable? 
 [1 marks] 
[Total: 20 marks] 
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Question 9 (Metabolomics and screening technologies) 
Give a structure or structures consistent with each of the following sets of 1H NMR 
data for compound C9H11NO2 – a local anesthetic (explain your answer).  
i)   triplet    δ 1.35 3H 
ii)   singlet (broad)   δ 4.10 2H 
iii)   quartet    δ 4.30 2H 
iv)   doublet    δ 6.12 2H 
v)   doublet    δ 7.84 2H  
 
Give a structure or structures consistent with each of the following sets of 13C NMR 
data for compound C3H6Cl2 (explain your answer).  
i)   quartet    δ 22.4 
ii)   triplet     δ 49.5 
iii)   doublet    δ 55.8  
 
Refer to the mass spectrum of 2-methylbutane shown below to answer the following 
questions.  
i. Which peak represents M+? 
ii. Which peak represents the base peak?  
iii. Propose structures for the fragment ions at m/z = 57, 43, and 29.  
 
 [20 marks] 
[Total: 20 marks]   
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Question 10 (Natural product chemistry) 
(a) Classify the following terpenes and terpenoids and determine the number of isoprene units 
in each structure. 
  
[5 marks] 
(b) What are ‘alkaloids’?  Explain how humans recognised uses for plant alkaloids. Give 
example of a natural and a synthetic alkaloid that can be used as a therapeutic agent. 
[5 marks] 
(c) Explain the reasons for differing water solubilities of alkaloids referencing relative proton 
affinity. Draw the structures of the agents that you use as examples (cannot be the agent 
used for part (a)). Describe how an alkaloid’s ionisation can affect its biological role. 
[5 marks] 
(d) Describe how a therapeutic agent can be biosynthesised from amino acids 
 [5 marks] 
[Total: 20 marks]  
 
End of Section B 
 
End of Exam Paper 
 
